CLAIMS:

1. A compound of formula (I)



(I)

wherein

n is 1, 2 or 3;

R1 is C_2-C_{10}alkyl, C_2-C_{10}alkenyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, C_4-C_{10}cycloalkylalkyl or C_4-C_{10}cycloalkenylalkyl wherein one $-CH_2-$ within any cycloalkyl moiety is optionally substituted by -O- or -S- and wherein each group is optionally substituted with from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, C_1-C_4alkyl, C_1-C_4alkylthio (optionally substituted with from 1 to 3 halogen atoms) and C_1-C_4alkoxy (optionally substituted with from 1 to 3 halogen atoms);

R2 is independently at each occurrence selected from H and C_1-C_4alkyl;

R3 is H or C_1-C_4alkyl;

R4 is H, halogen, hydroxy, cyano, C_1-C_4alkyl or C_1-C_4alkoxy;

R5 is H, halogen, hydroxy, cyano, C_1-C_4alkyl or C_1-C_4alkoxy; and

Heteroaryl is

(i) a 5- or 6-membered monocyclic heteroaromatic group optionally substituted with 1, 2, 3 or 4 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkylthio (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridinyl, pyrazolyl,

phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group, or

(ii) an 8-, 9- or 10-membered bicyclic heteroaromatic group optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkylthio (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group;

or a pharmaceutically acceptable salt thereof, for use in a method for treatment of the human or animal body by therapy.

2. A compound of formula (I)



(I)

wherein

n is 1, 2 or 3;

R1 is C_2-C_{10}alkyl, C_2-C_{10}alkenyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkenyl, C_4-C_{10}cycloalkylalkyl or C_4-C_{10}cycloalkenylalkyl wherein one $-CH_2-$ within any cycloalkyl moiety is optionally substituted by -O- or -S- and wherein each group is optionally substituted with from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently

selected from hydroxy, cyano, C_1-C_4alkyl, C_1-C_4alkylthio (optionally substituted with from 1 to 3 halogen atoms) and C_1-C_4alkoxy (optionally substituted with from 1 to 3 halogen atoms);

R2 is independently at each occurrence selected from H and C_1-C_4alkyl;

R3 is H or C_1-C_4alkyl;

R4 is H, halogen, hydroxy, cyano, C_1-C_4alkyl or C_1-C_4alkoxy;

R5 is H, halogen, hydroxy, cyano, C_1-C_4alkyl or C_1-C_4alkoxy; and

Heteroaryl is

(i) a 5- or 6-membered monocyclic heteroaromatic group optionally substituted with 1, 2, 3 or 4 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkylthio (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group, or

(ii) an 8-, 9- or 10-membered bicyclic heteroaromatic group optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkylthio (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group;

or a pharmaceutically acceptable salt thereof, with the proviso that the compounds



,



and



are excluded.

3. A compound as claimed in Claim 1 or Claim 2 wherein n is 1.

4. A compound as claimed in any preceding Claim wherein R2 is H.

5. A compound as claimed in any preceding Claim wherein R3 is H.

6. A compound as claimed in any preceding Claim wherein R4 is H.

7. A compound as claimed in any preceding Claim wherein R5 is H.

8. A compound as claimed in any one of Claims 1 to 7 wherein R1 is C_2-C_{10}alkyl optionally substituted with from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, C_1-C_4alkyl, C_1-C_4alkylthio (optionally substituted with from 1 to 3 halogen atoms) and C_1-C_4alkoxy (optionally substituted with from 1 to 3 halogen atoms).

9. A compound as claimed in any one of Claims 1 to 7 wherein R1 is C_4-C_{10}cycloalkylalkyl wherein one $-CH_2-$ within the cycloalkyl moiety is optionally substituted by -O- or -S- and wherein the group is optionally substituted with from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, C_1-

C_4alkyl, C_1-C_4alkylthio (optionally substituted with from 1 to 3 halogen atoms) and C_1-C_4alkoxy (optionally substituted with from 1 to 3 halogen atoms).

10. A compound as claimed in any one of Claims 1 to 9 wherein Heteroaryl is a 5- or 6-membered monocyclic heteroaromatic group optionally substituted with 1, 2, 3 or 4 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkylthio (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group.

11. A compound as claimed in any one of Claims 1 to 9 wherein Heteroaryl is a 5- or 6-membered monocyclic heteroaromatic group optionally substituted with 1 or 2 substituents (depending on the number of available substitution positions) each independently selected from halo, C_1-C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group.

12. A compound as claimed in any one of Claims 1 to 9 wherein Heteroaryl is a furanyl, thienyl, pyrazolyl, thiazolyl or pyridinyl group each of which is optionally substituted with 1 or 2 substituents each independently selected from halo, C_1-C_2alkyl (optionally substituted with 1, 2 or 3 F atoms) and

C_1-C_2alkoxy (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group.

13. A compound as claimed in any one of Claims 1 to 9 wherein Heteroaryl is an 8-, 9- or 10-membered bicyclic heteroaromatic group optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms), C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4thioalkyl (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group.

14. A compound as claimed in any one of Claims 1 to 9 wherein Heteroaryl is an 8-, 9- or 10-membered bicyclic heteroaromatic group optionally substituted with 1 or 2 substituents (depending on the number of available substitution positions) each independently selected from halo, C_1-C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group.

15. A compound as claimed in any one of Claims 1 to 9 wherein Heteroaryl is imidazo[2,1-b][1,3]thiazolyl, indolyl, benzofuranyl, benzothienyl, 1,3-benzothiazolyl, 2,1,3-benzothiadiazolyl, quinolinyl or isoquinolinyl group each of which is optionally substituted with 1 or 2 substituents each independently selected from halo, C_1-C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms) and C_1-C_4alkoxy (optionally substituted with 1, 2 or 3 F

atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within the group.

16. A pharmaceutical composition comprising a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent, excipient or carrier.

17. A method of inhibiting the uptake of one or more monoamines selected from serotonin, dopamine and norepinephrine in a mammal, comprising administering to a mammal in need of such inhibition an effective amount of a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof.

18. The use of a compound of formula (I) as defined in Claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for inhibiting the uptake of one or more monoamines selected from serotonin, dopamine and norepinephrine.